Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 11:2022:6125120.
doi: 10.1155/2022/6125120. eCollection 2022.

Efficacy and Mechanism of Trimebutine Maleate Combined with Lactulose in the Treatment of Constipation-Predominant Irritable Bowel Syndrome in the Elderly

Yeping Zhou  1 , Dujuan Yang  2 , Wenjun Gu  3   4
Affiliations

Efficacy and Mechanism of Trimebutine Maleate Combined with Lactulose in the Treatment of Constipation-Predominant Irritable Bowel Syndrome in the Elderly

Yeping Zhou et al. Emerg Med Int. .

Retraction in

Abstract

Objective: Study on the efficacy and mechanism of trimebutine maleate combined with lactulose in the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in the elderly.

Methods: From March 2019 to March 2021, 102 elderly patients with IBS-C were randomly divided into the observation group (51 cases) and the control group (51 cases). The observation group was treated with trimebutine maleate combined with lactulose, while the control group was treated with lactulose. Comparison of the clinical effects of the two groups. Comparison of vasoactive intestinal peptide (VIP) levels, neuropeptide Y (NPY) levels, and quality of life scores before and after treatment between the two groups. Documentation of adverse reactions during treatment.

Results: The improvement of clinical symptoms in the observation group was significantly better than that in the control group, and the difference is statistically significant (P < 0.05). The level of VIP after treatment in the observation group was significantly lower than that in the control group and before treatment, and the differences were statistically significant (P < 0.05). The level of NPY after treatment in the observation group was significantly higher than that in the control group and before treatment, and the differences were statistically significant (P < 0.05). The scores of dietary restrictions and health worries in the control group after treatment were significantly higher than those before treatment, and the differences were statistically significant (P < 0.05). The scores of anxious, behavioral conflict, dietary restrictions, health worries, social response, and family relationship in the observation group after treatment were significantly higher than those in the control group and before treatment, and the differences were statistically significant (P < 0.05). There were no serious adverse effects in either group during the treatment period, with some patients experiencing dizziness and dry mouth, which improved after discontinuation of the drug, without special intervention.

Conclusion: Trimebutine maleate combined with lactulose can improve clinical symptoms and quality of life in elderly patients with IBS-C, and its mechanism of action may be related to the regulation of the body's VIP and NPY levels.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Comparison of IBS-QOL scores between the two groups of patients (scores, ‾x ± s). Note: compared with the same group before treatment, ∗P < 0.05; compared with the control group after treatment, ΔP < 0.05. (a) Anxious. (b) Behavioral conflict. (c) Body image. (d) Dietary restrictions. (e) Health worries. (f) Social response. (g) Sexuality. (h) Family relationship.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Demir A. M., Kuloglu Z., Kansu A. Treatment of childhood functional constipation: Comparison of Senna, trimebutine and lactulose. Türkiye Çocuk Hastalıkları Dergisi . 2020;14(4):295–301.
    1. Quitadamo P., Isoldi S., Mallardo S. Scientific evidence for the treatment of children with irritable bowel syndrome. Current Pediatric Reviews . 2021;17(2):92–102. - PubMed
    1. Sandhu B. K., Paul S. P. Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment. World Journal of Gastroenterology . 2014;20(20):p. 6013. doi: 10.3748/wjg.v20.i20.6013. - DOI - PMC - PubMed
    1. Li C. Y., Li S. C. Treatment of irritable bowel syndrome in China: a review. World Journal of Gastroenterology . 2015;21(8):p. 2315. doi: 10.3748/wjg.v21.i8.2315. - DOI - PMC - PubMed
    1. Pesce M., Puoti M. G., Rybak A., et al. Pharmacological interventions for pediatric irritable bowel syndrome. Expert Opinion on Pharmacotherapy . 2022;23(1):91–103. doi: 10.1080/14656566.2021.1976753. - DOI - PubMed

Publication types

LinkOut - more resources